Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2011

View Archived Issues

StemCells begins phase I/II neural stem cell trial in spinal cord injury

Tumor-targeted nonclustered nanoparticles effective as MRI probes

Iron chelator M-30 may be beneficial in amyotrophic lateral sclerosis

ACADIA Pharmaceuticals presents new muscarinic acetylcholine receptor agonists

Start-up biotech company ImmusanT focuses on celiac disease immunotherapy

Novel HIV integrase inhibitors patented by Merck & Co.

Biodel selects two ultrarapid-acting insulin formulations for clinical development

Novel series of protein kinase inhibitors presented by Merck & Co.

Novel tyrosine-protein kinase BTK inhibitors presented by Bristol-Myers Squibb

University of Virginia presents new sphingosine kinase inhibitors

Anavex Life Sciences cleared to conduct phase I ANAVEX 2-73 study in Germany

Seattle Genetics and Millennium extend antibody-drug conjugate agreement

Safety and tolerability of GT-MAb 2.5-GEX seen in phase I trial in advanced/metastatic cancer

Daiichi Sankyo postpones Japanese launch of Memary tablets for Alzheimer's due to earthquake

Unigene begins dosing in phase II study of oral parathyroid hormone for osteoporosis

Boehringer Ingelheim obtains rights to Acuform technology and Glumetza data

Pluristem Therapeutics and NYU Medical Center partner to treat diabetic foot ulcers

Researchers describe protein aggregation inhibitor with potential for neurodegenerative diseases

Vernalis begins dosing patients in phase I trial of pain candidate V-158866

Cleveland Clinic grants Apeiron option to license SHP-1 inhibitors

Chinese health authorities approve Novo Nordisk's Victoza for type 2 diabetes

Agennix completes enrollment of phase III FORTIS-M trial of talactoferrin in NSCLC

In vivo protective effects of carbon nanotubes against ischemic brain injury

Src disruption enhances sensitivity of multiple myeloma cells to Chk1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...